Courtesy of Benzinga.
Last week, shares of Pozen Inc. (NASDAQ: POZN) rose the most in four months after announcing positive top-line results from two pivotal Phase 3 clinical trials. Will shares continue higher based on fundamentals and more upcoming catalysts?
Last week, the Chapel Hill, North Carolina-based firm said the newly released information from the studies is essential to progress their drug candidate’s (PA32540) partnership discussions in the United States, and that it will continue to move forward with preparations for a third quarter NDA submission with the FDA.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.
